The technology of BioCopy provides an effective head start in identifying the intricate complexities of the immune system to push the boundaries of future tumor and autoimmune therapies. Using our state-of-the-art microarray technology, we accelerate the processes of immunoprofiling and lead screening of T-cell receptors (TCRs) against a variety of antigen-HLA complexes, achieving speed and efficiency in our drug development process.
